



## CORPORATE FACT SHEET

---

### Corporate Overview

PEAK Surgical, a medical device company founded in August 2005, developed the PEAK<sup>®</sup> Surgery System, a new tissue dissection system based on a proprietary technology that represents an important advance in radiofrequency surgical technologies. The company is committed to providing physicians with an advanced single device that cuts tissue as precisely as a scalpel, while controlling bleeding as effectively as traditional electrosurgery without causing extensive collateral thermal damage to tissues – a revolutionary benefit that fills a critical market gap.

### The PEAK Surgery System and PlasmaBlade<sup>™</sup>

The company's flagship product, the PEAK Surgery System, includes the PULSAR<sup>®</sup> Generator and the PEAK PlasmaBlade<sup>™</sup> family of disposable, low-temperature surgical cutting and coagulation devices. The generator supplies pulsed plasma radiofrequency energy to the PlasmaBlade to incise tissue and control bleeding.

The PlasmaBlade family includes the:

- PlasmaBlade 4.0, which is designed to cut through all types of soft tissue, including skin, fat and muscle
- PlasmaBlade Needle, which has a fine needlepoint tip and is specifically designed for ultra-precise surgical procedures
- PlasmaBlade EXT, which is designed for use in surgical procedures requiring an extended-reach tip.

Unlike most radiofrequency-based surgical products that use continuous voltage waveforms to cut tissue, the PULSAR Generator supplies pulsed plasma-mediated electrical discharges through the PlasmaBlade. Because the radiofrequency energy is provided through short on-and-off pulses via a highly insulated cutting electrode, the PlasmaBlade cuts at an average temperature that is half that of a conventional electrosurgery device and can be as low as 50 degrees Centigrade. This temperature reduction results in significantly less damage to surrounding tissues compared to traditional electrosurgical devices. The PlasmaBlade can dissect tissue in a wet or dry surgical field.

### Validated Technology with Broad Applications

PEAK Surgical's pulsed plasma-mediated discharges and electrode insulation techniques were originally invented at the Hansen Experimental Physics Laboratory and Department of Ophthalmology at Stanford University and developed by PEAK Surgical.

The PEAK Surgery System is cleared for use in the United States for general, plastic and reconstructive, ENT (ear, nose and throat), gynecologic, orthopedic, arthroscopic, spinal and neurological surgical procedures, and for use in general surgery in the EU. Since U.S. Food and Drug Administration clearance, surgeons in the United States have used the PlasmaBlade in more than 500 surgical procedures, including in general, gynecologic, cardiothoracic and plastic and reconstructive surgeries.

Electrosurgery represents a \$1 billion market in the United States. PEAK Surgical believes that its technology may have applications in more than two million surgical procedures each year.

## **Robust Clinical Development Program**

PEAK Surgical has completed the first of a series of clinical studies, called the PRECISE Studies (Pulsed Plasma Radiofrequency Energy to ReduCe Thermal Injury and Improve Surgical HEaling), to evaluate the use of the PEAK Surgery System in plastic and reconstructive, gynecologic and oncologic surgery.

The first PRECISE Outcomes study focused on patient recovery following abdominoplasty and showed that PlasmaBlade patients demonstrated a better overall recovery than standard of care patients (scalpel and traditional electrosurgery).

Preclinical study results have demonstrated that the PlasmaBlade is associated with effective bleeding control, minimal thermal tissue injury, positive wound healing, minimal scarring and inflammation, and improved surgical incision healing and strength compared with traditional electrosurgical devices.

<b>MANAGEMENT TEAM</b>	<b>BOARD OF DIRECTORS</b>
<b>John R. Tighe</b> President and CEO	<b>Faruk K. Amin</b> Lehman Brothers
<b>Andre P. Bessette</b> Vice President of Marketing	<b>Mark S. Blumenkranz, M.D.</b> Professor, Chairman of Department of Ophthalmology, Stanford University
<b>John J. Cifarelli</b> Vice President of Sales	<b>Joyce Erony</b> Managing Director, Signet Healthcare Partners
<b>Paul O. Davison</b> Vice President of Research and Development	<b>Anders D. Hove, M.D.</b> General Partner, Venrock Associates
<b>Lori A. Perpich-Munoz</b> Vice President of Finance	<b>John P. McLaughlin</b> CEO, Anesiva, Inc.
<b>Jeremy C. Edinger</b> Director of Operations	<b>Terry E. Spraker, Ph.D.</b> Former CEO, Solarant Medical, Inc.
<b>Gwen Drain</b> Director of Human Resources	<b>John R. Tighe</b> President and CEO, PEAK Surgical
<b>An N. Nguyen</b> Director of Quality and Regulatory Affairs	

## **Investors**

The company is privately held and has raised more than \$29 million in three rounds of private financing. In February 2008, the company closed a Series C financing that raised \$21 million and was led by Signet Healthcare Partners with Lehman Brothers and Venrock Associates also participating. The Series A and B rounds were led jointly by Lehman Brothers, Inc. and Venrock Associates.

PEAK Surgical has 50 employees.

## **Corporate Headquarters**

PEAK Surgical, Inc.  
2464 Embarcadero Way  
Palo Alto, CA 94303  
Phone: 650.331.3020  
Fax: 650.331.3293  
media@peaksurgical.com  
[www.peaksurgical.com](http://www.peaksurgical.com)

*PEAK Surgical, Inc., June 2009*